News for Biocon Limited (BIOCON.NS)

The Nifty Pharma index closed 0.54 per cent up at 22662.7.

The Nifty Pharma index closed 0.32 per cent down at 22593.9.

M&M, Wipro, Tech Mahindra, Nestle, SBI and Infosys led the gainers of Nifty 50 pack. Lack of fresh triggers, mixed global cues, and Q1 earnings caution keep benchmark indices range-bound; PSU Bank stocks rally on reform hopes

The NSE Nifty index was trading 38.0 points down at 25157.8

The Nifty Pharma index was trading 0.35 per cent up at 22303.75.

The Nifty Pharma index closed 0.09 per cent down at 22365.05.

The Nifty Pharma index closed 0.42 per cent up at 22204.25.

The Nifty Pharma index closed 0.32 per cent up at 22110.8.

The Nifty Pharma index closed 0.01 per cent up at 22041.25.

The Nifty Pharma index was trading 0.19 per cent up at 21969.5.

Biocon Biologics delivers 100 million insulin cartridges to Malaysia, commercializes biosimilars in key global markets with $600 million investment.

TORONTO, Ontario, Canada and BENGALURU, Karnataka, India, June 27, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for Yesafili™ (aflibercept), a biosimilar to Eylea® (aflibercept) injection, in vial and prefilled syringe presentations, 2 mg/0.05 mL on June 26, 2025. This approval paves the way for the launch of YESAFILI in Canada, scheduled for July 4, 2025. YESAFILI is the first biosimilar to EYLEA to be approved by Health Canada.

JSW Paints nears acquisition of AkzoNobel, Hitachi Energy secures Power Grid order, Power Mech wins Bihar solar contract.

The Nifty Pharma index was trading 0.0 per cent at 21803.85.

Zen Technologies acquires TISA Aerospace, SIS Ltd focuses on tech, India Cements sells subsidiary, Hilton Metal Forging receives certification.

India markets ended lower on Thursday, dragged by IT and financial stocks amid Fed hawkishness and Middle East tensions. Broad-based selling hit mid and smallcaps. Analysts remain cautious with bearish sentiment likely unless Nifty crosses 24,850.

The Nifty Pharma index was trading 0.94 per cent down at 21831.4.

As indicated by the GIFT Nifty, the NSE Nifty 50 may likely open near 25,000 levels, which is a key resistance zone. The key support zone is at 24,850.

Buzzing stocks: Tanla buyback price; Reliance-Asian Paints stake sale; Jio’s Aladdin